low age at onset of parkinson 's disease , and at the commencement of levodopa therapy , the duration of levodopa treatment and a high dose of levodopa seem to be significant risk factors for the development of response fluctuations , but not the pretreatment duration of parkinson 's disease nor the disability of the patients .
C0023570
levodopa
C0030567
parkinson 's disease